secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pyxis Oncology, Inc. (PYXS)
CIK:        0001782223
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0000950170-24-097054
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pyxis Oncology Q2 net loss $17.3M; cash $157.2M funds into 2H 2026
------------------------------------------------------------------

- Net loss $17.3M ($0.29/shr) vs $15.9M ($0.41/shr) in Q2 2023; R&D spend $13.9M.
- Cash, equivalents and short-term investments $157.2M as of June 30, 2024; runway into 2H 2026.
- PYX-201 Phase 1: 72 subjects dosed; preliminary data (efficacy, safety, PK) expected fall 2024.
- PYX-106 Phase 1: 33 subjects dosed; preliminary data (PK/PD) expected by year-end 2024.
- Outstanding shares: 58,942,243 as of August 14, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782223/000095017024097054/0000950170-24-097054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782223/000095017024097054/pyxs-20240814.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-097054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer